The Use of ATP-MgCl2 in the Treatment of Injury and Shock.
Annual rept. 1 Sep 83-14 Aug 84,
YALE UNIV NEW HAVEN CONN DEPT OF SURGERY
Pagination or Media Count:
The purpose of our studies was to determine the safety and hemodynamic response of adenosine triphosphatemagnesium chloride infusion in normal awake human volunteers. In accordance with a protocol approved by the Human Investigation Committee, five healthy adult male volunteers received an intravenous infusion of adenosine triphosphatemagnesium chloride o.1-0.4mgkgmin on four separate occasions. The total dose infused was 3, 6, 10 and 30mgkg n20 studies. Hemodynamic measurements were made at end exhalation in the supine position and included heart rate and systolic, dyastolic and mean blood pressure. Continuous electrocardiographic monitoring of lead II was performed. All hemodynamic changes returned to normal within 2 minutes after the ATP-MgCl2 infusion was discontinued pNS. Sodium, potassium, hemoglobin and glucose levels did not change during or after ATP-MgCl2 administration. All subjects experienced transient mild nausea at infusion rates greater than 0.3mgkgmin. There were no delayed side effects. ATP-MgCl2 is a potent vasodilator. As demonstrated in this study, the increase in cardiac output offset the decrease in total systemic resistance. Thus, blood pressure MBP was maintained.
- Medicine and Medical Research